Avalo Therapeutics, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-12-17$19.25 RISE2026-04-28$12.86 PEAK2026-05-07$22.87 141d | -33.2% 132d | Missed | Missed | — | — | +77.8% 9d | Missed |
DROP2025-12-10$19.95 RISE2026-02-05$13.15 PEAK2026-03-03$18.85 83d | -34.1% 57d | Missed | Missed | — | — | +43.3% 26d | Missed |
DROP2025-03-27$8.73 RISE2025-05-28$3.59 PEAK2025-08-22$9.88 148d | -58.9% 62d | Missed | Missed | — | — | +175.2% 86d | Missed |
DROP2024-10-25$14.44 RISE2025-02-27$6.60 PEAK2025-03-27$8.73 153d | -54.3% 125d | Missed | Missed | — | — | +32.3% 28d | Missed |
DROP2024-10-25$14.44 RISE2025-01-15$6.32 PEAK2025-03-27$8.73 153d | -56.2% 82d | Missed | Missed | — | — | +38.1% 71d | Missed |
DROP2024-04-30$17.12 RISE2024-08-30$7.00 PEAK2024-10-25$14.44 178d | -59.1% 122d | Missed | Missed | — | — | +106.3% 56d | Missed |
DROP2024-03-28$21.75 RISE2024-05-17$9.59 PEAK2024-06-25$13.90 89d | -55.9% 50d | Missed | Missed | — | — | +44.9% 39d | Missed |
DROP2023-09-13$53.76 RISE2024-01-17$4.02 PEAK2024-03-28$21.75 197d | -92.5% 126d | Missed | Missed | — | — | +441.0% 71d | Missed |
DROP2023-06-23$1,060.80 RISE2023-09-11$20.40 PEAK2023-09-13$53.76 82d | -98.1% 80d | Missed | Missed | — | — | +163.5% 2d | Missed |
DROP2023-01-04$1,233.60 RISE2023-05-11$576.00 PEAK2023-06-23$1,060.80 170d | -53.3% 127d | Missed | Missed | — | — | +84.2% 43d | Missed |
DROP2022-12-15$1,399.20 RISE2023-03-29$386.40 PEAK2023-06-23$1,060.80 190d | -72.4% 104d | Missed | Missed | — | — | +174.5% 86d | Missed |
DROP2022-06-23$1,609.92 RISE2022-09-27$710.40 PEAK2022-11-02$1,656.00 132d | -55.9% 96d | Missed | Missed | — | — | +133.1% 36d | Missed |
DROP2022-04-01$2,508.48 RISE2022-08-02$840.00 PEAK2022-10-26$1,471.20 208d | -66.5% 123d | Missed | Missed | — | — | +75.1% 85d | Missed |
DROP2022-01-05$5,068.80 RISE2022-05-13$720.00 PEAK2022-06-23$1,609.92 169d | -85.8% 128d | Missed | Missed | — | — | +123.6% 41d | Missed |
DROP2022-01-03$5,212.80 RISE2022-05-11$720.00 PEAK2022-06-23$1,609.92 171d | -86.2% 128d | Missed | Missed | — | — | +123.6% 43d | Missed |
1–15 / 25 1 / 2 | |||||||
Citizens analyst Jason N. Butler maintains Avalo Therapeutics (NASDAQ:AVTX) with a Market Outperform and lowers the price target from $62 to $55.
Avalo Therapeutics reported better-than-expected Q1 loss due to positive trial results. Analysts maintain Buy ratings with lowered price targets.
Wedbush analyst Robert Driscoll maintains Avalo Therapeutics (NASDAQ:AVTX) with a Outperform and lowers the price target from $40 to $34.
Analyst ratings for top names changed: Doximity cut to neutral, National Vision lowered price target, Starbucks upgraded to buy, Commercial Metals raised to buy, Wix.Com target lowered, MDxHealth target slashed, Avalo Therapeutics target cut, Crowdstrike target raised.
Mizuho analyst Joseph Catanzaro maintains Avalo Therapeutics (NASDAQ:AVTX) with a Outperform and raises the price target from $39 to $45.
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $40 to $35.
Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(0.98) per share which beat the analyst consensus estimate of $(1.13) by 13.27 percent. This is a 21.6 percent increase over losses of $(1.25) per share from
Achieved positive topline results in Phase 2 LOTUS trial of abdakibart in moderate to severe hidradenitis suppurativa and plan to advance into a registrational phase 3 programCompleted public...
Piper Sandler analyst Yasmeen Rahimi maintains Avalo Therapeutics (NASDAQ:AVTX) with a Overweight and raises the price target from $48 to $60.
Avalo Therapeutics (AVTX) is now well-positioned after strong Phase 2 LOTUS results for abdakibart in hidradenitis suppurativa (HS).
Biotech stock Avalo Therapeutics skyrocketed to a two-year high Wednesday on positive results for its skin disease treatment.
The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session.
Avalo Therapeutics Inc (NASDAQ:AVTX) shares are surging after the company delivered a major clinical win, strengthened its balance sheet with a new offering and picked up fresh support from Wall Street analysts.
Before the US market kicks off on Wednesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Dow Jones up 500 points, DaVita Inc (DVA) shares rise after better-than-expected earnings and raised guidance. Other gaining stocks include EVC, BLMN, MNKD, FLEX, HUT, AVTX, COMP, VCYT, and SSRM.
Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.
Citizens analyst Jason N. Butler maintains Avalo Therapeutics (NASDAQ:AVTX) with a Market Outperform and raises the price target from $52 to $62.
Wedbush analyst Robert Driscoll maintains Avalo Therapeutics (NASDAQ:AVTX) with a Outperform and raises the price target from $29 to $40.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| AVTX | +16.34% | -11.29% | -12.17% | +298.75% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +13.37% | -5.58% | -8.73% | +286.06% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 2.88M | $42.99M | 0.00% | Added+1207.1% | 2026-03-31 |
| Citadel | multi-strat | 916.1K | $13.68M | 0.02% | Added+46.0% | 2026-03-31 |
| RenTech | quant | 120.1K | $1.79M | 0.00% | Added+556.4% | 2026-03-31 |
| StateStreet | passive | 71.7K | $1.07M | 0.00% | Trimmed-9.6% | 2026-03-31 |
| TwoSigma | quant | 64.4K | $961.87K | 0.00% | Trimmed-56.5% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-12upcoming | -0.63 | — | — |
| 2026-05-13 | -1.07 | -0.98 | +8.55% |
| 2026-03-23 | -1.49 | -0.37 | +75.25% |
| 2025-11-06 | -1.64 | -2.19 | -33.70% |
| 2025-08-07 | -1.40 | -1.92 | -37.00% |
| 2025-05-12 | -1.60 | -1.25 | +22.12% |
| 2025-03-20 | 1.67 | -2.74 | -264.56% |
| 2024-11-07 | -1.19 | 0.98 | +182.35% |
| 2024-08-12 | -6.70 | 4.21 | +162.84% |
| 2024-05-13 | -1.18 | -141.00 | -11849.15% |
| 2024-03-29 | -4.80 | -113.04 | -2255.02% |
| 2023-11-09 | -264.00 | -26.40 | +90.00% |
| 2023-08-03 | -168.00 | -141.60 | +15.71% |
| 2023-05-04 | -232.80 | -204.00 | +12.37% |
| 2023-03-29 | -156.00 | -249.60 | -60.00% |
| 2022-11-07 | -315.20 | 81.60 | +125.89% |